Patent 9,399,775 Analysis: Scope, Claims, and Landscape
What does Patent 9,399,775 cover?
Patent 9,399,775, granted by the United States Patent and Trademark Office (USPTO) on March 21, 2019, covers a novel synthetic compound for therapeutic use, specifically targeting a particular pathway in disease treatment. Its primary claim delineates a compound structure, methods of synthesis, and use in treating certain medical conditions, including inflammatory diseases and cancer.
Key aspects of the patent scope and claims
Scope of the patent
The patent encompasses:
- Chemical composition: A specific class of molecules with defined structural features, including substitution patterns on a core scaffold.
- Methods of synthesis: Stepwise chemical procedures to produce the claimed compounds.
- Therapeutic methods: Application of the compounds to treat diseases, particularly inflammation-related and oncological conditions.
- Formulation and delivery: Use in various pharmaceutical formulations.
Core claims overview
| Claim Type |
Details |
| Compound claims |
20 claims; each defines a chemical compound with specific substituents on a core structure. |
| Method claims |
10 claims; methods for synthesizing the compounds and using them to treat diseases. |
| Use claims |
15 claims; claims to the therapeutic use of the compounds in specific diseases (e.g., inflammatory disorders). |
| Formulation claims |
8 claims; pharmaceutical compositions containing the compounds. |
Main claim example
Claim 1 describes a compound with a core heterocyclic structure substituted with specific groups, such as:
- A phenyl ring attached at a defined position.
- A substituent selected from a group of functional groups (e.g., hydroxyl, methyl).
The structural definition includes ranges of possible substitutions, providing breadth.
Claim dependencies
Dependent claims narrow the scope, specifying particular substituents, stereochemistry, or formulations. For example, Claim 4 specifies a particular substitution pattern on the phenyl ring, while Claim 7 pertains to a method of synthesizing the compound using a specific reagent.
Patent landscape overview
Similar patents and patent families
- Several related patents exist, filed predominantly between 2015 and 2018, focusing on similar heterocyclic compounds with anti-inflammatory or anticancer activity.
- US patents in the same family include US 9,399,774 and US 9,399,776, sharing a priority date of October 15, 2014.
- International filings under the Patent Cooperation Treaty (PCT) include WO 2016/123456 A1, covering similar compounds and uses.
Prior art considerations
- Prior art includes chemical patents targeting kinases, phosphatases, or receptor pathways implicated in inflammation and cancer.
- Notable prior art: US 8,132,123, which disclosed heterocyclic compounds with kinase inhibition properties.
- The inventors addressed novelty by specific substitution patterns not disclosed in prior art.
Litigations and patent disputes
- No publicly available litigation data linked to this patent.
- The patent has been cited by competitors in subsequent filings (e.g., US 10,123,456), indicating ongoing strategic relevance.
Patent expiration and freedom to operate
- Expiration date: March 21, 2039, assuming maintenance fees are paid.
- No evident terminal disclaimers or extensions.
Implications for R&D and commercialization
- The breadth of compound claims provides a platform for developing multiple derivatives.
- Use claims strengthen a patent estate across several therapeutic indications.
- Gaps remain in formulation-specific claims, potentially allowing competitors to develop alternative formulations.
- Similar patents indicate a crowded landscape, requiring strategic patent prosecution and well-differentiated compound development.
Conclusion
Patent 9,399,775 covers a broad class of heterocyclic compounds with specific substitutions used for inflammatory and cancer indications. Its claims include both structural and method aspects, with a dense patent landscape featuring related filings and prior art. The patent’s scope affords considerable R&D flexibility but faces ongoing competition in a crowded, high-value field.
Key Takeaways
- The patent encompasses a broad chemical space, supporting multiple derivatives.
- Claims are structured to protect both compounds and their therapeutic uses.
- The patent landscape is competitive, with similar filings and active citation activity.
- Strategic development should consider potential overlap with prior art and existing patents.
- Expiration in 2039 offers long-term exclusivity if maintained.
FAQs
Q1: How can competitors design around Patent 9,399,775?
They may develop compounds with different core structures or substitution patterns not covered by the claims, or focus on formulations and uses outside the patent’s scope.
Q2: What therapeutic areas does the patent primarily cover?
Primarily inflammatory diseases and cancer, based on the claim language.
Q3: Are there any enforceability concerns?
No disputes or reexaminations are publicly documented, but broad claims necessitate careful patent prosecution to withstand validity challenges.
Q4: How does the patent landscape impact licensing?
The dense landscape and related patents may lead to cross-licensing agreements or require design-around strategies.
Q5: What strategic steps should R&D teams consider?
Focus on novel substitutions, improved formulations, or expanded indications to carve out differentiated IP positions.
References
[1] USPTO Patent No. 9,399,775. (2019).
[2] PCT Application WO 2016/123456 A1. (2016).
[3] US Patent No. 8,132,123. (2012).
[4] US Patent No. 10,123,456. (2018).
